Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - PENPULIMAB OBTAINED BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR THIRD-LINE TREATMENT OF METASTATIC NASOPHARYNGEAL CARCINOMA

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

Website:www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

PENPULIMAB OBTAINED BREAKTHROUGH THERAPY DESIGNATION

FROM FDA FOR THIRD-LINE TREATMENT OF METASTATIC NASOPHARYNGEAL CARCINOMA

The board of directors (the "Board") of Sino Biopharmaceutical Limited (the "Company", together with its subsidiaries, the "Group") announces that "Penpulimab" (product name: Annike (τ̵̙); research and development code: AK105), a PD-1 monoclonal antibody drug co-developed by the Group and Akeso, Inc., has obtained breakthrough therapy designation from the Food and Drug Administration of the United States ("FDA") for third-line treatment of patients with metastatic nasopharyngeal carcinoma.

This is another significant progress Penpulimab has made in the United States after receiving the fast track designation and orphan drug designation from the FDA for third-line treatment of metastatic nasopharyngeal carcinoma.

Breakthrough therapy designation aims to accelerate new drug development and can be applied to drugs that are designed to treat severe diseases and have shown in early clinical studies significant improvement over existing therapies. Drugs with breakthrough therapy designation will receive closer guidance and various forms of support from senior FDA officials during the development process to ensure that patients will be provided with new treatment options in the shortest time. The success in obtaining breakthrough therapy designation for Penpulimab from the FDA in respect of third-line treatment of metastatic nasopharyngeal carcinoma will significantly support and accelerate the commercialization plan of Penpulimab in the United States.

Currently, Penpulimab may be applied to major indications such as liver cancer, gastric cancer, lung cancer, Hodgkin's lymphoma, nasopharyngeal cancer, etc.

By order of the Board

Sino Biopharmaceutical Limited

Tse, Theresa Y Y

Chairwoman

Hong Kong, 30 March 2021

As at the date of this announcement, the Board of the Company comprises nine Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Mr. Li Kwok Tung Donald.